Introduction
Metabolic syndrome refers to a state in which metabolic risk factors for cardiovascular disease are clustered in individuals, and it increases the risk of morbidity and mortality due to cardiovascular disease (1) . Criteria for the diagnosis of metabolic syndrome have recently been established in Japan (2) . The growing concern about the increasing prevalence of metabolic syndrome has generated substantial interest in the metabolic effects of antihypertensive drugs (3) .
Recently, several lines of evidence suggest that angiotensinconverting enzyme (ACE) inhibitors and particular angiotensin II receptor blockers (ARBs) may improve insulin sensitivity and decrease the risk for type 2 diabetes (4).
Recently, the ARB telmisartan has been found to effectively activate peroxysome proliferator-activated receptorγ (PPARγ), a well-known target for insulin-sensitizing antidiabetic drugs (5 Cl i n i c a l B a c k g r o u n d a n d Ch a r a c t e r i s t i c s o f t h 
Methods

Study subjects
Fifty
Blood pressure control
At the end of the 4-week treatment period, significant mean reductions from baseline in seated trough SBP of T a b l e 2 . Co n c o mi t a n t T r e a t me n t s T a b l e 3 . E f f e c t s o f T e l mi s a r t a n a n d Va l s a r t a n o n S y s t o l i c B l o o d P r e s s u r e ( S B P ) a n d Di a s t o l i c B l o o d P r e s s u r e ( DB P ) about 10 mmHg were found in both telmisartan-treated and valsartan-treated patients (both p<0.05) ( 
Glucose metabolism
After 4 weeks of therapy with telmisartan or valsartan, there were no significant changes from baseline in BMI, HbA1c and FPG (Fig. 1, Table 4 (Fig. 2, p<0. (6) . In the present study, we also found an insulin sensitizing effect of telmisartan in hypertensive patients with metabolic syndrome. We also showed for the first time that a lower dose of telmisartan (20 mg (10, 11) . This effect may be related to the insulin-sensitizing effect of telmisartan in our study. On the other hand, recent studies have shown that telmisartan ameliorated mitochondrial energy metabolism in skeletal muscle and enhanced glucose uptake in adipocytes accompanied by an increase in GLUT4 expression (12, 13) F i g u r e 1 . Ch a n g e s i n h o me o s t a s i s mo d e l a s s e s s me n t o f i n s u l i n r e s i s t a n c e ( HOMA-R) a f t e r 4  we e k s o f t e l mi s a r t a n a n d v a l s a r t a n a d mi n i s t r a t i o n . 
05, r=0.475).
Lipid metabolism
There were no significant changes from baseline in the lipid profiles of patients who had received telmisartan or valsartan for 4 weeks. Telmisartan was associated with a mean 6.2% decrease from baseline in plasma TG level, but this decrease was not statistically significant.
Discussion
Several studies have already shown that treatment with telmisartan at a dose of 40 mg resulted in a significant improvement in glucose metabolism in insulin-resistant subjects
. Among the various ARBs, telmisartan exhibits the highest partition coefficient, reflecting high lipophilicity and extensive penetration into target tissues and organs, and this pharmacological pro-
T a b l e 4 . E f f e c t s o f T e l mi s a r t a n a n d Va l s a r t a n o n B o d y Ma s s I n d e x ( B MI ) a n d Gl u c o s e Me t a b o l i s m
T a b l e 5 . E f f e c t s o f T e l mi s a r t a n a n d Va l s a r t a n o n S e r u m L i p i d P r o f i l e file might be involved in the strong insulin-sensitizing effect of telmisartan (14) .
It was found in this study that the extent of decrease in HOMA-R had a significant correlation with HOMA-R at baseline (Fig. 2) F i g u r e 2 . Co r r e l a t i o n b e t we e n t h e l o g h o me o s t a s i s mo d e l a s s e s s me n t o f i n s u l i n r e s i s t a n c e ( HOMA-R) a t b a s e l i n e a n d t h e c h a n g e s i n HOMA-R d u r i n g t r e a t me n t i n e a c h p a t i e n t e x a mi n e d . (20) . In the present study, no significant change of body weight or other parameters related to metabolic syndrome was observed. This might be due to the short observation period. 
Study limitations
Conclusions
In hypertensive patients with metabolic syndrome, treatment with telmisartan for 4 weeks had a significant insulinsensitizing effect compared with the effect of valsartan. This effect of telmisartan tended to be prominent in a highly insulin-resistant state and was observed at an even lower dose (20 mg/day) . For the treatment of hypertension with metabolic syndrome, consideration should be given to this ameliorating effect of telmisartan on glucose metabolism.
